Starpharma Holdings Net Income 2011-2021 | SPHRY
Starpharma Holdings net income from 2011 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Starpharma Holdings Annual Net Income
(Millions of US $) |
| 2021 |
$-15 |
| 2020 |
$-10 |
| 2019 |
$-10 |
| 2018 |
$-8 |
| 2017 |
$6 |
| 2016 |
$-17 |
| 2015 |
$-16 |
| 2014 |
$-13 |
| 2013 |
$-5 |
| 2012 |
$-14 |
| 2011 |
$-9 |
Starpharma Holdings Quarterly Net Income
(Millions of US $) |
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.225B |
$0.002B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
